Almirall, S.A. Stock

Equities

ALM

ES0157097017

Pharmaceuticals

Market Closed - BME 11:35:30 2024-05-17 EDT 5-day change 1st Jan Change
9.27 EUR -0.97% Intraday chart for Almirall, S.A. +1.20% +10.03%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 980M 1.07B 1.45B Sales 2025 * 1.08B 1.17B 1.6B Capitalization 1.94B 2.11B 2.87B
Net income 2024 * 24M 26.08M 35.49M Net income 2025 * 63M 68.46M 93.16M EV / Sales 2024 * 1.98 x
Net cash position 2024 * 2.34M 2.55M 3.47M Net cash position 2025 * 77.1M 83.79M 114M EV / Sales 2025 * 1.73 x
P/E ratio 2024 *
77.2 x
P/E ratio 2025 *
29.8 x
Employees 1,904
Yield 2024 *
2.02%
Yield 2025 *
2%
Free-Float 34.06%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.97%
1 week+1.20%
Current month+8.17%
1 month+13.39%
3 months+7.67%
6 months+7.73%
Current year+10.03%
More quotes
1 week
9.12
Extreme 9.115
9.96
1 month
8.23
Extreme 8.23
9.96
Current year
7.85
Extreme 7.85
9.96
1 year
7.16
Extreme 7.16
10.08
3 years
7.16
Extreme 7.16
15.35
5 years
7.16
Extreme 7.16
18.50
10 years
7.16
Extreme 7.16
19.36
More quotes
Managers TitleAgeSince
Chief Executive Officer - 14-07-24
Director of Finance/CFO 54 19-11-10
Chief Tech/Sci/R&D Officer - 21-07-06
Members of the board TitleAgeSince
Director/Board Member - 15-12-31
Director/Board Member 65 20-06-30
Director/Board Member 65 18-12-31
More insiders
Date Price Change Volume
24-05-17 9.27 -2.52% 166,941
24-05-16 9.51 +1.39% 290,154
24-05-15 9.38 +1.96% 338,265
24-05-14 9.2 -0.92% 708,051
24-05-13 9.285 +1.36% 814,503

Delayed Quote BME, May 17, 2024 at 11:35 am

More quotes
Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
9.27 EUR
Average target price
11.28 EUR
Spread / Average Target
+21.65%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW